-6.25% to Target, JP Morgan Cazenove Reaffirms Neutral Rating for AstraZeneca PLC (LON:AZN) Stock

AstraZeneca PLC (LON:AZN) Rating

In an analyst report revealed to clients and investors on Monday morning, AstraZeneca PLC (LON:AZN) stock Neutral was kept at JP Morgan Cazenove. They currently have a GBX 3900.00 target price on the stock. JP Morgan Cazenove’s target price would suggest a potential downside of -6.25% from the company’s current price.

Out of 29 analysts covering AstraZeneca PLC (LON:AZN), 16 rate it “Buy”, 3 “Sell”, while 14 “Hold”. This means 48% are positive. GBX 97.43 is the highest target while GBX 36 is the lowest. The GBX 66.41 average target is 14.83% above today’s (GBX 4142.21) stock price. AstraZeneca PLC was the topic in 209 analyst reports since July 23, 2015 according to StockzIntelligence Inc. HSBC maintained the stock on April 7 with “Hold” rating. Natixis maintained it with “Neutral” rating and GBX 4456 target price in a March 24 report. JP Morgan maintained the shares of AZN in a report on April 5 with “Neutral” rating. Barclays Capital maintained the firm’s rating on March 24. Barclays Capital has “Equal Weight” rating and GBX 5000 price target. Finally, Cantor Fitzgerald maintained the stock with “Buy” rating in a March 31 report.

The stock decreased 0.61% or GBX 25.29 on April 8, hitting GBX 4142.21. AstraZeneca plc (LON:AZN) has declined 2.85% since September 9, 2015 and is downtrending. It has underperformed by 7.91% the S&P500.

-6.25% to Target, JP Morgan Cazenove Reaffirms Neutral Rating for AstraZeneca PLC (LON:AZN) Stock

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to reports earnings on April, 22. They expect $0.51 earnings per share, down 5.56% or $0.03 from last year’s $0.54 per share. AZN’s profit will be $1.27B for 14.43 P/E if the $0.51 EPS becomes reality. After $0.94 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -45.74% negative EPS growth.

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 52.13 billion GBP. The Firm discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. It has 26.19 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca PLC - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Add Comment